Cancer Worry Score and perception of risk for pretreatment dysplastic Barrett’s oesophagus compared with the other cohorts.
| Cancer Worry Score | VAS | ||||||
| Total mean (SD) | Category % Normal (<10) | Category % Borderline (10-11) | Category % Positive (>12) | Coefficient (95% CI) | Pretreatment DBO versus p value | Pretreatment DBO versus other domains for VAS scoring p values | |
| Pretreatment DBO | 12.55 (4.85) | 22.7% N=15 | 10.1% N=7 | 67.2% N=44 | – | – | – |
| NDBO | 12.19 (4.57) | 31.8% (121) | 15.8% (66) | 50.9% (194) | −0.99 (−2.12 to 0.13) | 0.084 | 0.713 |
| Retro DBO | 12.67 (4.95) | 33.3% (16) | 16.7% (8) | 50.0% (24) | 0.59 (−0.94 to 2.12) | 0.451 | 0.967 |
| GORD | 10.88 (4.98) | 45.7% (59) | 10.9% (14) | 43.4% (56) | −3.30 (−4.61 to −1.98) | <0.001* | 0.003* |
| Colonic polyps | 11.58 (3.93) | 36.2% (54) | 12.8% (19) | 51.0% (76) | −1.29 (−2.53 to −0.46) | 0.042* | 0.438 |
| Healthy | 10.02 (3.31) | 47.9% (23) | 22.9% (11) | 29.2% (14) | −4.26 (−6.00 to −2.53) | <0.001* | 0.773 |
*, Denotes statistical significance; DBO, dysplastic Barrett’s oesophagus; GORD, gastroesophageal reflux disease; NDBO, non-dysplastic Barrett’s oesophagus; VAS, Visual Analogue Scale.